| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | 96.861 | 112.680 | 152.015 | 101.137 | 153.008 | 143.509 | 155.310 | 147.313 |
| Total Income - EUR | - | - | 96.861 | 112.680 | 152.693 | 102.454 | 158.108 | 150.130 | 160.788 | 149.800 |
| Total Expenses - EUR | - | - | 50.204 | 69.199 | 138.111 | 61.729 | 125.040 | 139.685 | 62.654 | 104.749 |
| Gross Profit/Loss - EUR | - | - | 46.657 | 43.482 | 14.581 | 40.725 | 33.067 | 10.445 | 98.134 | 45.052 |
| Net Profit/Loss - EUR | - | - | 45.689 | 42.355 | 13.061 | 39.692 | 31.655 | 9.010 | 96.558 | 41.447 |
| Employees | - | - | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Check the financial reports for the company - Noul Ort8Imed Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | 1.905 | 9.579 | 9.393 | 12.063 | 17.305 | 13.723 | 9.746 | 18.550 |
| Current Assets | - | - | 73.807 | 149.655 | 144.550 | 160.804 | 164.428 | 108.214 | 140.245 | 209.765 |
| Inventories | - | - | 25.677 | 64.188 | 15.747 | 15.426 | 27.393 | 15.699 | 71.101 | 124.610 |
| Receivables | - | - | 19.818 | 16.592 | 76.256 | 76.347 | 74.759 | 4.178 | 16.227 | 13.069 |
| Cash | - | - | 28.312 | 68.875 | 52.546 | 69.031 | 62.276 | 88.336 | 52.917 | 72.086 |
| Shareholders Funds | - | - | 66.700 | 127.705 | 96.147 | 134.016 | 162.699 | 97.142 | 128.713 | 213.669 |
| Social Capital | - | - | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | 9.012 | 31.529 | 57.796 | 38.850 | 19.034 | 24.795 | 21.278 | 14.646 |
| Income in Advance | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "3250 - 3250" | |||||||||
| CAEN Financial Year |
3250
|
|||||||||
Comments - Noul Ort8Imed Srl